Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Individualizing Care for Patients With Triple-Negative Breast Cancer

Source: Smarter. Stronger. Together: Optimizing Personalized Triple-Negative Breast Cancer Care for Providers and Patients
In this podcast episode, listen to breast cancer experts Mark Pegram, MD, and Sara Tolaney, MD, MPH, engage in a discussion from a live CCO Cancer Conversations webinar on optimal treatment strategies for patients with TNBC.
Mark Pegram, MD
Sara Tolaney, MD, MPH
Released: January 18, 2023

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:

  • Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC
  • Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC
  • Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC
  • Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
  • Role of PARP inhibitors in the treatment of TNBC

Information on this Educational Activity

Faculty

Mark Pegram, MD

Professor
Medical Oncology
Stanford University
Palo Alto, California

Mark Pegram, MD: consultant/advisor/speaker: AstraZeneca/Daiichi Sankyo, Gilead Sciences, Roche/Genentech.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, AstraZeneca, ARC Therapeutics, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead Sciences, Infinity Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana Therapeutics, Myovant, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zymeworks; steering committee: CytomX, Lilly, OncXerna; researcher (paid to institution): AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead Sciences, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC, in partnership with Smart Patients, Inc.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by an educational grant from
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings